TITLE:
Clinical Observation of Neoadjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Report of 24 Cases
AUTHORS:
Anxin Wang, Jinjun Li
KEYWORDS:
Neoadjuvant Chemotherapy, Adjuvant Chemotherapy, Colon Cancer, Efficacy, Risk Factors
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.13,
December
14,
2017
ABSTRACT: Background: Neoadjuvant chemotherapy is the systemic
chemotherapy before the start of local chemotherapy or radiotherapy. At
present, neoadjuvant chemotherapy in the high-risk phase II (AJCC TNM stage II
period, including T3N0M0 and T4N0M0) treatment of colon cancer reported less. The
authors discussed the efficacy and safety of neoadjuvant chemotherapy in 24
patients with high-risk stage II colorectal cancer. Method: Forty-eight patients with stage II colorectal
cancer were randomly divided into experimental group and control group, the
postoperative complications, the side effects of chemotherapy drugs and the
effect of chemotherapy drugs on the tumor were observed. The quality of life,
survival time and tumor recurrence or metastasis was compared between the two
groups. Result: 1) The incidence of complications in the neoadjuvant chemotherapy group was
20.8%, the incidence of adjuvant chemotherapy was 25%, and the overall
complication rate was 22.9%. P values were greater than 0.05. 2) Through
the comparison of the two groups of toxic and side effects, after SPASS
software analysis, obtained P >
0.05, the two groups were not statistically significant. 3) After 3 - 4
courses of preoperative chemotherapy, CR (complete remission) and PD (disease
progression) patients were 0 cases, PR
(partial remission) was 11 (45.8%), NC/SD (no change) was 13 (54.2%). 4) Through
the comparison of the quality of life of the two groups of patients, from the
function, symptoms and the overall situation to statistics, P value 0.05,
This comparison makes sense. 5) The
1-year survival rate was 100% (24/24) in the control group, with a 3-year survival
rate of 92% (22/24) and a 5-year survival rate of 75% (9/12). All
survival rates in the experimental group were 100% (24/24). 6) There
were no recurrence or metastasis cases in the neoadjuvant chemotherapy group,
and 2 cases of recurrence and 1 case of metastasis in the adjuvant chemotherapy
group were compared with the recurrence or metastasis after tumor operation. The
chi-square test is not statistically significant. Conclusion: Neoadjuvant
chemotherapy plays a role in patients with high-risk second-stage colon cancer,
the experimental group benefited significantly, especially in quality of life
and survival time. At the same time, neoadjuvant chemotherapy is also a safe
treatment.